UPDATE 1-Sarepta jumps on drug approval hopes after FDA critic departs

Sept 14 (Reuters) - Shares of Sarepta Therapeutics Inc

rose as much as 29 percent after a key critic of its

muscle-wasting drug left the U.S. Food and Drug Administration

ahead of the agency's...

Read more